Although the investigations in vivo are still insufficient, the data suggest that DPP-4 inhibitors and GLP-1 receptor agonists may improve hepatic steatosis and suppress the progression of hepatic fibrosis. This evidence concerns the gene GLP1R and fatty liver disease.